Background: Current and recent smoking have been associated with a greater risk of
smokers; P-trend = 0.05). Among men without comorbidities, mean telomere length did not differ by smoking status in stromal cells or cancer cells.
Conclusion:
Telomere variability in prostate cells may be one mechanism through which smoking influences poor prostate cancer outcomes.
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| INTRODUCTION
Current or recent cigarette smoking has been associated with an increased risk of advanced stage and high grade prostate cancer at diagnosis, prostate cancer progression independent of stage and grade, and prostate cancer mortality, but not prostate cancer incidence. 1, 2 The biologic mechanism(s) underlying these associations have not been established, though one possible mechanism may be through alterations in telomere length.
Telomeres, which protect the chromosomes from degradation and recombination, can become dysfunctional when there is incomplete replication during DNA synthesis, alterations of telomere-binding proteins involved in telomere maintenance, or DNA damage via oxidative stress. [3] [4] [5] Though cancer cells, including prostate cancer cells, [6] [7] [8] typically have significantly shorter telomeres than normal cells from the same tissue, cancer cell maintenance of telomeres improves viability. 9 Among cancer cells, variability in telomere length may indicate more genetic instability, and thus could promote the development of a more aggressive phenotype. 10 We recently reported that, among men surgically treated for prostate cancer, those with shorter telomeres in prostate cancer associated stromal cells (ie, stromal cells in the same tissue microarray [TMA] spot as cancer) and those with more variability in telomere length among prostate cancer cells had a higher risk of poor prostate cancer outcomes, in particular prostate cancer death.
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Cigarette smoking, a source of oxidative stress, has been associated with shorter telomere length in peripheral blood leukocytes in some large, high quality studies (eg, ref. 12 ). However, the influence of cigarette smoking on telomere length in prostate cells is unknown. Because cigarette smoking can influence many co-morbid conditions that we hypothesize may also influence telomere length, we conducted sub-analyses among men who had no major co-morbid conditions prior to prostate cancer diagnosis. With respect to comorbidities, on the baseline questionnaire, and on each follow-up questionnaire, men reported whether they had the following conditions professionally diagnosed: high blood pressure, elevated cholesterol, diabetes, and myocardial infarction (heart attack). We categorized men who answered no to all of these conditions on each of the 1986, 1988, and 1990 questionnaires (eg, the questionnaires prior to prostate cancer diagnosis) as men without a major comorbid condition diagnosed before prostate cancer (n = 271; never smokers: 51%, former smokers who quit ≥10 years ago: 29%, and current/recent smokers: 20%).
Additionally, because there appears to be an interaction between smoking and vitamin E use in the association with fatal prostate cancer such that vitamin E use offsets the association between smoking and fatal prostate cancer, 13 we performed a sub-analysis restricted to men not taking supplemental vitamin E (Vitamin E ≤15 mg; n = 350; never smokers: 49%, former smokers who quit ≥10 years ago: 32%, and current/recent smokers: 19%).
| Tissue collection and tissue microarray construction
The ascertainment of prostate cancer in the HPFS has been described previously. 11 With participant permission, tissue blocks of the prostatectomy specimens were obtained from the original pathology departments. H&E-stained tissue sections were re-reviewed by study pathologists and assigned a standardized Gleason sum. 14 For this project, we used five tissue microarrays (TMAs) that had been constructed, 11 sampling at least three areas of the tumor focus that was the largest and/or had the highest Gleason sum.
| Measurement of telomere length
Tissue microarray sections containing areas of adenocarcinoma and benign tissue were stained using a telomere-specific fluorescence in situ hybridization (FISH) probe and 4′,6-diamidino-2-phenylindole (DAPI) for labeling total nuclear DNA. In sub-analyses, we restricted to men (1) without major comorbid conditions diagnosed before prostate cancer and (2) not taking supplemental vitamin E. All analyses were performed using SAS v 9.2 (SAS Institute, Cary, NC). All statistical tests were two-sided, with P < 0.05 considered to be statistically significant.
| RESULTS
Men who currently smoked or quit smoking within the prior 10 years (subsequently referred to as "current/recent" smokers) were similar to men who had quit smoking 10 or more years prior (subsequently referred to as "former" smokers) and men who had never smoked on most characteristics (Table 1) . Former smokers were older than current/recent and never smokers. Compared with former smokers, current/recent smokers accumulated significantly more pack years.
Compared with former and never smokers, current/recent smokers were significantly more likely to have a Gleason sum of 4 + 3 or higher, and pathologic stage T3b or higher, though this difference in stage was not statistically significant.
| Stromal cells, basal epithelial cells, and luminal epithelial cells
When all men were categorized by their pre-diagnostic smoking status, there was no difference in telomere length or variability in telomere length in stromal cells (Table 2) . Similarly, among men without major prediagnostic comorbidities, there was no difference in telomere length in stromal cells. However, among men without major pre-diagnostic comorbidities, current/recent smokers had 29.3% more variability in telomere length in stromal cells as compared to never smokers (Ptrend = 0.0005; Table 2 ). The results were similar when restricting to men without the most common co-morbidities (ie, high blood pressure and high cholesterol; P-trend = 0.002). Among men who did not take a vitamin E supplement, there was no significant difference in variability in telomere length in stromal cells as compared to never smokers (Ptrend = 0.1). There was no difference in telomere length or variability in telomere length by smoking status in basal epithelial cells or in luminal epithelial cells in all men, or in men without co-morbidities (P > 0.05).
| Cancer cells
When all men were categorized by their pre-diagnostic smoking status, there was no difference in telomere length or variability in telomere length in cancer cells (Table 3) . Similarly, among men without major prediagnostic comorbidities, there was no difference in telomere length in cancer cells. However, among men without major pre-diagnostic comorbidities, current/recent smokers had 27.7% more variability in telomere length in cancer cells as compared to never smokers (Ptrend = 0.05; Table 3 ). Also, the results were similar when restricting to men without the most common co-morbidities (ie, high blood pressure or high cholesterol; P-trend = 0.05). Among men who did not take a vitamin E supplement, there was no significant difference in variability in telomere length in cancer cells by smoking status (P-trend = 0.31). Cigarette smoking was not associated with telomere length or telomere length variability in prostate cells in men overall. Because cigarette smoking influences several co-morbid conditions that we hypothesize may also influence telomere length, we conducted subanalyses among men without major comorbidities. In these sub-analyses, we observed increased cell-to-cell telomere length variability in stromal cells among men who currently or recently smoked. Though we no longer observed this pattern in sub-analyses restricting to men who did not take a vitamin E supplement, which has been shown to mitigate the association between smoking and fatal prostate cancer. 13 In our prior analyses, we did not observe an association between stromal cell telomere length variability and prostate cancer death after adjustment for prognostic factors, 11 but did observe greater telomere length variability in stromal cells of men who were overweight/obese. 15 Thus, it is plausible that lifestyle factors, like cigarette smoking and obesity, 15 have a biologic influence on telomere length variability in stromal cells. It is unknown, however, whether variability in telomere length in prostate stromal cells influences any point in the natural history of prostate carcinogenesis.
Because telomere dysfunction is a dynamic process that both promotes tumorigenesis and can be a consequence of cancer development, it is less clear how cigarette smoking could influence telomere length variability in cancer cells at the point that a tumor is detectable (eg, the time of telomere measurement in this study). Nevertheless, among men without major comorbidities, we also observed increased cell-to-cell telomere length variability in prostate cancer cells among men who currently or recently smoked. In our prior study, we observed an increased risk of poor prostate cancer outcomes among men surgically treated for prostate cancer who had increased telomere length variability in prostate cancer cells after adjustment for prognostic factors. 11 It is possible that increased telomere length variability in cancer cells reflects more generalized genomic instability, which has been related to more aggressive features in cancer, 10 including prostate cancer. 16, 17 It is unclear whether cigarette smoking contributes directly to increased telomere length variability among cancer cells or if increased variability is marking more aggressive disease among smokers.
Our study, which, to our knowledge, is the first to investigate the influence of cigarette smoking on cell-to-cell telomere length variability in prostate tissue may inform the observation that current or recent cigarette smoking is associated with an increased risk of poor outcomes among men with prostate cancer. However, this study was not large enough to assess telomere length variability as a potential mediator in the association between current or recent cigarette smoking and prostate cancer with a lethal phenotype. Because all of the men in this study had prostate cancer, we do not know whether our results for prostate cell telomere length variability would be similar in a cohort of men at risk for prostate cancer. The smoking status of participants in this study was well characterized. The method used to measure telomere length was validated, state-of-the-art, and provided single cell resolution, 6 that allowed comparison by each cellular compartment and estimation of cell-to-cell variability in telomere length. In interpreting our findings for variability in telomere length in stromal cells by smoking status, we cannot distinguish between the variability in telomere length being due to variability in length among the same array of stromal cell types among smokers and non-smokers versus a different array of stromal cell types that have inherent differences in telomere length among smokers and non-smokers. We did not observe evidence to support the latter interpretation. Finally, we performed multiple primary tests; the results for smoking and stromal cell variability (Ptrend = 0.0005) in men without major comorbidities remained statistically significant when using the Bonferroni corrected P-value (P < 0.002) for deeming statistical significance.
The mechanisms that underlie the association between cigarette smoking and poor prostate cancer-specific outcomes are currently unknown. Because cigarette smoking has been associated with shorter leukocyte telomere length in some large, high quality studies (eg, 
